Use of AT-1 receptor antagonist or AT2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors

Details for Australian Patent Application No. 2003266433 (hide)

Owner Novartis AG

Inventors De Gasparo, Marc; Ganter, Sabina Maria; Bullock, Gillian Rosemary

Agent Davies Collison Cave

Pub. Number AU-B-2003266433

Parent 30430

Filing date 2 December 2003

Wipo publication date 8 January 2004

Acceptance publication date 10 August 2006

International Classifications

A61K 31/41 (2006.01) - having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole

A61K 31/415 (2006.01) - 1,2-Diazoles

A61K 31/44 (2006.01) - Non-condensed pyridines

A61K 31/455 (2006.01) - Nicotinic acid, i.e. niacin

Event Publications

18 December 2003 Complete Application Filed

8 January 2004 Application Open to Public Inspection

  Published as AU-B-2003266433

8 January 2004 Complete Application Filed

10 August 2006 Application Accepted

  Published as AU-B-2003266433

7 December 2006 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003266434-Modular orthopaedic implant apparatus and method

2003266432-Acoustic monitoring system